International Flavors & Fragrances Inc.

IFF · NYSE · USD

Does removing Food Ingredients and its stranded costs leave a faster-growing, higher-margin IFF, or do weak North American Health and commodity fragrance ingredients offset the simplification?

Last 4 earnings calls · through Q2 FY2026

Bull case

  • Portfolio focus after divestitures

    The bull case is that selling Food Ingredients leaves three businesses that grow faster and earn better margins than the company did as a whole.

  • Volume-led growth

    Growth now comes from volume and new customer wins rather than price, which management says carries strong incremental margins as sales rise.

  • Stranded costs removed

    Management plans to strip out the overhead left behind by the divestiture, which would lift segment margins without needing more sales.

  • Capital returns and debt paydown

    Proceeds are earmarked to cut debt and buy back stock, which the company expects to offset dilution created by the transaction.

Bear case

  • Commodity ingredient competition

    The bear case is that much of the external fragrance ingredient business competes on price with Asian producers and the shift to specialties keeps slipping.

  • North American health weakness

    The health business in North America has not recovered as promised, and the company now points to market conditions rather than to its own execution.

  • Middle East cost pressure

    Energy and logistics inflation tied to the Middle East is arriving before customer surcharges take effect, and Fine Fragrance demand in the region is weaker.

  • Cash conversion

    Cash generation has trailed reported profit because of divestiture charges, inventory and separation costs, while capital spending is rising at the same time.

Bull and bear points

Growth & Execution

In short: Volume growth is broad across Taste, Scent and H&B, but North American Health and Middle East scent lag.

Bull · 3

  • Taste, Scent and Health & Biosciences all grew volume in the second quarter

    Taste revenue was $688 million, Scent $665 million and Health & Biosciences $601 million, with growth coming from volume and new wins rather than price.

    Q2 FY2026 call

  • Food Ingredients moved from an option study to a signed sale with CVC

    A year ago management would only say it was evaluating alternatives and would update in February; it has now signed a deal valuing the unit at about $4.3 billion and can focus capital on three businesses.

    Tone shiftQ3 FY2025 → Q2 FY2026

  • R&D spending on the remaining businesses has risen to about 9% of sales

    Management raised research spending from about 7% of sales and says the commercial and innovation pipelines built over two years start contributing in the second half of 2026 and into 2027.

    Q2 FY2026 call
Bear · 2

  • The North American health business is still contracting after a promised second-half recovery

    Management told investors the business would flatten in the first half of 2026 and grow in the second half; it now describes US market conditions as still challenging, pushing the recovery out again.

    Tone shiftQ4 FY2025 → Q2 FY2026

  • Middle East disruption is hitting Fine Fragrance volumes and customer supply chains

    Fine Fragrance is the highest-margin part of Scent, so slower demand and packaging delays for customers in the region reduce both sales and the sales mix in the second quarter and third quarter.

    Q1 FY2026 call

Profitability & Financial Strength

In short: Margins are expanding and debt is down, while stranded costs and higher capital spending hold back cash.

Bull · 2

  • Gross margin expanded to 43.7% in the second quarter

    Productivity and favorable net pricing lifted gross margin by 0.7 points, and management says productivity gains are large enough to pay for the reinvestment it is making.

    Q4 FY2025 call

  • Capital returns moved from a $500 million program to a $2.5 billion authorization

    Management started in 2025 with a buyback sized only to offset dilution; it now plans to return about $2.5 billion once Food Ingredients is sold, alongside more than $1 billion of debt reduction.

    Tone shiftQ3 FY2025 → Q2 FY2026
Bear · 2

  • Free cash flow is only 5.4% of revenue over the past twelve months

    Divestiture-related charges and a deliberate inventory build absorbed cash, and the Food Ingredients separation is expected to take a couple of hundred million dollars more out of working capital.

    Q2 FY2026 call

  • Capital spending is rising just as the company is trying to improve cash flow

    Capital spending was $621 million, or 6.2% of revenue, in the last twelve months, and management expects to stay at the top of its 5% to 6% range for a year or two.

    Q2 FY2026 call

Market Position

In short: IFF has scale in Taste and Scent and can pass on costs, but commodity fragrance ingredients face Asian rivals.

Bull · 1

  • Fine Fragrance kept growing through the Middle East disruption

    Scent revenue was $665 million in the second quarter, up 8%, with Fine Fragrance finishing slightly positive even after customers struggled to get packaging into the region.

    Q2 FY2026 call
Bear · 1

  • Revenue fell 12.5% over three years while operating margin dropped to negative 3.5%

    The business depends on consumer demand and customer ordering patterns, and the last cycle showed sales and operating margin can fall together when customers destock.

    Filed financials